Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-05-27

A european malaria vaccine development consortium: euromalvac 1

Objective

Pre-clinical development and testing with various adjuvants of candidate vaccines developed from Plasmodium falciparum Merozoite Surface Proteins and parasite-encoded antigens expressed on infected erythrocytes. Preparation of the Malaria Vaccine Testing Facility at Nijmegen University to carry out pre-clinical and clinical trials of malaria vaccines.
Brief description:
The consortium will co-ordinate work in 13 laboratories in 6 European countries on immunogen validation, vaccine design and synthesis, and pre-clinical and clinical testing of candidate malaria vaccines in a series of linked projects. The objectives are:
Pre-clinical development and testing of Plasmodium falciparum Merozoite Surface Protein 1 (MSP-1) C-terminal-based vaccines with alum and new experimental adjuvants. Defining the binding sites and biological activities of specific antibodies, thus designing more effective vaccine constructs using immunological and biochemical assays correlated with immunity.
N-terminal Block 2 sequences of MSP-1 will be inserted into Pichia pastoris vectors for expression at high yield, analysed for immunogenicity and reformulated in adjuvants for immunisation studies in Aotus monkeys.
Parasites will be identified which express variants of the Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1) that are commonly recognised by endemic sera. Objectives include : identifying cross-reactive epitopes, high-frequecy variants and mapping epitopes of PfEMP-1 ; inducing rodent and phage display antibodies against defined PfEMP-1 epitopes and determining whether specific human antibody responses to defined epitopes are associated with protection against disease.
Carrying out codon re-engineering and scaled up P.pastoris expression of P.falciparum AMA-1 constructs to obtain pure antigen for vaccine challenge studies in animal models.
Scaling-up production of Pf antigen R23 for vaccine formulation with alum and other adjuvants and dose-response experiments in animal models.
Collating the consortium's sera and parasite isolate banks to perform immuno-epidemiological services for all relevant consortium projects.
Preparing the Malaria Vaccine Testing Facility at Nijmegen University to carry out clinical trials of malaria vaccines.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSC - Cost-sharing contracts

Coordinator

University of Edinburgh
EU contribution
No data
Address
Old College South Bridge
EH1 1HN Edinburgh
United Kingdom

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (9)

My booklet 0 0